Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4+ T and Natural Killer Cells.

Barsoumian HB, Batra L, Shrestha P, Bowen WS, Zhao H, Egilmez NK, Gomez-Gutierrez JG, Yolcu ES, Shirwan H.

Cancer Res. 2019 Feb 15;79(4):783-794. doi: 10.1158/0008-5472.CAN-18-2401.

PMID:
30770367
2.

A DNA Vaccine Encoding SA-4-1BBL Fused to HPV-16 E7 Antigen Has Prophylactic and Therapeutic Efficacy in a Cervical Cancer Mouse Model.

Garza-Morales R, Perez-Trujillo JJ, Martinez-Jaramillo E, Saucedo-Cardenas O, Loera-Arias MJ, Garcia-Garcia A, Rodriguez-Rocha H, Yolcu E, Shirwan H, Gomez-Gutierrez JG, Montes-de-Oca-Luna R.

Cancers (Basel). 2019 Jan 15;11(1). pii: E96. doi: 10.3390/cancers11010096.

3.

Localized immune tolerance from FasL-functionalized PLG scaffolds.

Skoumal M, Woodward KB, Zhao H, Wang F, Yolcu ES, Pearson RM, Hughes KR, García AJ, Shea LD, Shirwan H.

Biomaterials. 2019 Feb;192:271-281. doi: 10.1016/j.biomaterials.2018.11.015. Epub 2018 Nov 13.

PMID:
30458362
4.

Synthetic poly(ethylene glycol)-based microfluidic islet encapsulation reduces graft volume for delivery to highly vascularized and retrievable transplant site.

Weaver JD, Headen DM, Coronel MM, Hunckler MD, Shirwan H, García AJ.

Am J Transplant. 2019 May;19(5):1315-1327. doi: 10.1111/ajt.15168. Epub 2018 Dec 5.

PMID:
30378751
5.

Local immunomodulation Fas ligand-engineered biomaterials achieves allogeneic islet graft acceptance.

Headen DM, Woodward KB, Coronel MM, Shrestha P, Weaver JD, Zhao H, Tan M, Hunckler MD, Bowen WS, Johnson CT, Shea L, Yolcu ES, García AJ, Shirwan H.

Nat Mater. 2018 Aug;17(8):732-739. doi: 10.1038/s41563-018-0099-0. Epub 2018 Jun 4.

6.

Adenovirus Lacking E1b Efficiently Induces Cytopathic Effect in HPV-16-Positive Murine Cancer Cells via Virus Replication and Apoptosis.

Martinez-Jaramillo E, Garza-Morales R, Wechman SL, Montes de Oca-Luna R, Saucedo-Cardenas O, Shirwan H, Yolcu E, McMasters KM, Gomez-Gutierrez JG.

Cancer Invest. 2018 Jan 2;36(1):19-27. doi: 10.1080/07357907.2018.1430812. Epub 2018 Feb 1.

7.

Current challenges for cancer vaccine adjuvant development.

Bowen WS, Svrivastava AK, Batra L, Barsoumian H, Shirwan H.

Expert Rev Vaccines. 2018 Mar;17(3):207-215. doi: 10.1080/14760584.2018.1434000. Epub 2018 Feb 8. Review.

8.

Temozolomide renders murine cancer cells susceptible to oncolytic adenovirus replication and oncolysis.

Garza-Morales R, Yaddanapudi K, Perez-Hernandez R, Riedinger E, McMasters KM, Shirwan H, Yolcu E, Montes de Oca-Luna R, Gomez-Gutierrez JG.

Cancer Biol Ther. 2018 Mar 4;19(3):188-197. doi: 10.1080/15384047.2017.1416274. Epub 2018 Jan 22.

9.

Vasculogenic hydrogel enhances islet survival, engraftment, and function in leading extrahepatic sites.

Weaver JD, Headen DM, Aquart J, Johnson CT, Shea LD, Shirwan H, García AJ.

Sci Adv. 2017 Jun 2;3(6):e1700184. doi: 10.1126/sciadv.1700184. eCollection 2017 Jun.

10.

Fas/Fas-Ligand Interaction As a Mechanism of Immune Homeostasis and β-Cell Cytotoxicity: Enforcement Rather Than Neutralization for Treatment of Type 1 Diabetes.

Yolcu ES, Shirwan H, Askenasy N.

Front Immunol. 2017 Mar 27;8:342. doi: 10.3389/fimmu.2017.00342. eCollection 2017. No abstract available.

11.

Mechanisms of Tolerance Induction by Hematopoietic Chimerism: The Immune Perspective.

Yolcu ES, Shirwan H, Askenasy N.

Stem Cells Transl Med. 2017 Mar;6(3):700-712. doi: 10.1002/sctm.16-0358. Epub 2017 Jan 3. Review.

12.

Protease-degradable microgels for protein delivery for vascularization.

Foster GA, Headen DM, González-García C, Salmerón-Sánchez M, Shirwan H, García AJ.

Biomaterials. 2017 Jan;113:170-175. doi: 10.1016/j.biomaterials.2016.10.044. Epub 2016 Oct 28.

13.

4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4+CD25+FoxP3+ T Regulatory Cell Suppression.

Barsoumian HB, Yolcu ES, Shirwan H.

PLoS One. 2016 Apr 6;11(4):e0153088. doi: 10.1371/journal.pone.0153088. eCollection 2016.

14.

SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer.

Srivastava AK, Yolcu ES, Dinc G, Sharma RK, Shirwan H.

Oncoimmunology. 2015 Jul 1;5(1):e1064580. eCollection 2016.

15.

Novel technologies to engineer graft for tolerance induction.

Woodward KB, Wang F, Zhao H, Yolcu ES, Shirwan H.

Curr Opin Organ Transplant. 2016 Feb;21(1):74-80. doi: 10.1097/MOT.0000000000000270. Review.

16.

SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines.

Srivastava AK, Dinc G, Sharma RK, Yolcu ES, Zhao H, Shirwan H.

Cancer Res. 2014 Nov 15;74(22):6441-51. doi: 10.1158/0008-5472.CAN-14-1768-A. Epub 2014 Sep 24.

17.

Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant.

Dinc G, Pennington JM, Yolcu ES, Lawrenz MB, Shirwan H.

Vaccine. 2014 Sep 3;32(39):5035-40. doi: 10.1016/j.vaccine.2014.07.015. Epub 2014 Jul 18.

PMID:
25045812
18.

The direct display of costimulatory proteins on tumor cells as a means of vaccination for cancer immunotherapy.

Shirwan H, Yolcu ES, Sharma RK, Zaho H, Grimany-Nuno O.

Methods Mol Biol. 2014;1139:269-85. doi: 10.1007/978-1-4939-0345-0_23.

PMID:
24619687
19.

SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Sharma RK, Yolcu ES, Shirwan H.

Expert Rev Vaccines. 2014 Mar;13(3):387-98. doi: 10.1586/14760584.2014.880340. Review.

20.

Fragmented sleep accelerates tumor growth and progression through recruitment of tumor-associated macrophages and TLR4 signaling.

Hakim F, Wang Y, Zhang SX, Zheng J, Yolcu ES, Carreras A, Khalyfa A, Shirwan H, Almendros I, Gozal D.

Cancer Res. 2014 Mar 1;74(5):1329-37. doi: 10.1158/0008-5472.CAN-13-3014. Epub 2014 Jan 21.

21.

CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models.

Sharma RK, Yolcu ES, Srivastava AK, Shirwan H.

PLoS One. 2013 Sep 16;8(9):e73145. doi: 10.1371/journal.pone.0073145. eCollection 2013.

22.

Immunomodulation with SA-FasL protein as an effective means of preventing islet allograft rejection in chemically diabetic NOD mice.

Yolcu ES, Zhao H, Shirwan H.

Transplant Proc. 2013 Jun;45(5):1889-91. doi: 10.1016/j.transproceed.2013.01.041.

23.

Posttransplantation systemic immunomodulation with SA-FasL-engineered donor splenocytes has robust efficacy in preventing cardiac allograft rejection in mice.

Zhao H, Woodward KB, Shirwan H, Grimany-Nuno O, Yolcu ES.

Transplant Proc. 2013 Jun;45(5):1805-7. doi: 10.1016/j.transproceed.2013.01.049.

24.

Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft-versus-host disease.

Yolcu ES, Kaminitz A, Mizrahi K, Ash S, Yaniv I, Stein J, Shirwan H, Askenasy N.

Exp Hematol. 2013 Oct;41(10):903-11. doi: 10.1016/j.exphem.2013.04.016. Epub 2013 Jun 4.

PMID:
23743300
25.

Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines.

Shirwan H, Sharma RK, Srivastava AK, Yolcu ES.

Oncoimmunology. 2013 Apr 1;2(4):e23440.

26.

Killer Treg cells ameliorate inflammatory insulitis in non-obese diabetic mice through local and systemic immunomodulation.

Kaminitz A, Yolcu ES, Mizrahi K, Shirwan H, Askenasy N.

Int Immunol. 2013 Aug;25(8):485-94. doi: 10.1093/intimm/dxt016. Epub 2013 May 8.

PMID:
23657001
27.

Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner.

Srivastava AK, Sharma RK, Yolcu ES, Ulker V, MacLeod K, Dinc G, Shirwan H.

PLoS One. 2012;7(11):e48463. doi: 10.1371/journal.pone.0048463. Epub 2012 Nov 8.

28.

SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ.

Madireddi S, Schabowsky RH, Srivastava AK, Sharma RK, Yolcu ES, Shirwan H.

PLoS One. 2012;7(8):e42459. doi: 10.1371/journal.pone.0042459. Epub 2012 Aug 1. Erratum in: PLoS One. 2012;7(8): doi/10.1371/annotation/88b557df-1e27-4a60-8b47-214a5cc3c707.

29.

Engineering of bone marrow cells with fas-ligand protein-enhances donor-specific tolerance to solid organs.

Askenasy EM, Shushlav Y, Sun Z, Shirwan H, Yolcu ES, Askenasy N.

Transplant Proc. 2011 Nov;43(9):3545-8. doi: 10.1016/j.transproceed.2011.08.046.

PMID:
22099838
30.

Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice.

Yolcu ES, Zhao H, Bandura-Morgan L, Lacelle C, Woodward KB, Askenasy N, Shirwan H.

J Immunol. 2011 Dec 1;187(11):5901-9. doi: 10.4049/jimmunol.1003266. Epub 2011 Nov 7.

31.

Effector and naturally occurring regulatory T cells display no abnormalities in activation induced cell death in NOD mice.

Kaminitz A, Yolcu ES, Askenasy EM, Stein J, Yaniv I, Shirwan H, Askenasy N.

PLoS One. 2011;6(6):e21630. doi: 10.1371/journal.pone.0021630. Epub 2011 Jun 27.

32.

Is durable macrochimerism key to achieving clinical transplantation tolerance?

Ildstad ST, Shirwan H, Leventhal J.

Curr Opin Organ Transplant. 2011 Aug;16(4):343-4. doi: 10.1097/MOT.0b013e328348e67a. No abstract available.

PMID:
21681096
33.

Killer Treg restore immune homeostasis and suppress autoimmune diabetes in prediabetic NOD mice.

Kaminitz A, Yolcu ES, Stein J, Yaniv I, Shirwan H, Askenasy N.

J Autoimmun. 2011 Aug;37(1):39-47. doi: 10.1016/j.jaut.2011.03.003. Epub 2011 Apr 15.

PMID:
21497486
34.

[Allograft tolerance induced by FasL chimeric protein decorated donor splenocytes].

Gu X, Yang J, Zhao H, Yolcu ES, Shirwan H.

Zhonghua Wai Ke Za Zhi. 2010 May 1;48(9):702-5. Chinese.

PMID:
20646556
35.

SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.

Sharma RK, Srivastava AK, Yolcu ES, MacLeod KJ, Schabowsky RH, Madireddi S, Shirwan H.

Vaccine. 2010 Aug 16;28(36):5794-802. doi: 10.1016/j.vaccine.2010.06.073. Epub 2010 Jul 4.

36.

Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy.

Sharma RK, Yolcu ES, Elpek KG, Shirwan H.

Cancer Gene Ther. 2010 Oct;17(10):730-41. doi: 10.1038/cgt.2010.29. Epub 2010 Jun 18.

37.

Tumor necrosis factor receptors support murine hematopoietic progenitor function in the early stages of engraftment.

Pearl-Yafe M, Mizrahi K, Stein J, Yolcu ES, Kaplan O, Shirwan H, Yaniv I, Askenasy N.

Stem Cells. 2010 Jul;28(7):1270-80. doi: 10.1002/stem.448.

38.

4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.

Sharma RK, Schabowsky RH, Srivastava AK, Elpek KG, Madireddi S, Zhao H, Zhong Z, Miller RW, Macleod KJ, Yolcu ES, Shirwan H.

Cancer Res. 2010 May 15;70(10):3945-54. doi: 10.1158/0008-5472.CAN-09-4480. Epub 2010 Apr 20.

39.

A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.

Schabowsky RH, Elpek KG, Madireddi S, Sharma RK, Yolcu ES, Bandura-Morgan L, Miller R, MacLeod KJ, Mittler RS, Shirwan H.

Vaccine. 2009 Dec 11;28(2):512-22. doi: 10.1016/j.vaccine.2009.09.127. Epub 2009 Oct 29.

40.

ProtEx technology for the generation of novel therapeutic cancer vaccines.

Schabowsky RH, Sharma RK, Madireddi S, Srivastava A, Yolcu ES, Shirwan H.

Exp Mol Pathol. 2009 Jun;86(3):198-207. doi: 10.1016/j.yexmp.2009.01.010. Epub 2009 Jan 31. Review.

41.

Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.

Sharma RK, Elpek KG, Yolcu ES, Schabowsky RH, Zhao H, Bandura-Morgan L, Shirwan H.

Cancer Res. 2009 May 15;69(10):4319-26. doi: 10.1158/0008-5472.CAN-08-3141. Epub 2009 May 12.

42.

Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein.

Yolcu ES, Gu X, Lacelle C, Zhao H, Bandura-Morgan L, Askenasy N, Shirwan H.

J Immunol. 2008 Jul 15;181(2):931-9.

43.

Longitudinal tracking of recipient macrophages in a rat chronic cardiac allograft rejection model with noninvasive magnetic resonance imaging using micrometer-sized paramagnetic iron oxide particles.

Ye Q, Wu YL, Foley LM, Hitchens TK, Eytan DF, Shirwan H, Ho C.

Circulation. 2008 Jul 8;118(2):149-56. doi: 10.1161/CIRCULATIONAHA.107.746354.

44.

Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.

Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H.

Curr Opin Investig Drugs. 2007 Dec;8(12):1002-8. Review.

PMID:
18058571
45.

Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.

Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H.

J Immunol. 2007 Dec 1;179(11):7295-304.

46.

Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis.

Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Shirwan H, Yaniv I, Askenasy N.

Exp Hematol. 2007 Oct;35(10):1601-12.

PMID:
17889725
47.

Fas transduces dual apoptotic and trophic signals in hematopoietic progenitors.

Pearl-Yafe M, Stein J, Yolcu ES, Farkas DL, Shirwan H, Yaniv I, Askenasy N.

Stem Cells. 2007 Dec;25(12):3194-203. Epub 2007 Sep 13.

48.
49.

Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions.

Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Yaniv I, Shirwan H, Askenasy N.

Stem Cells. 2007 Jun;25(6):1448-55. Epub 2007 Mar 15.

50.

A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model.

Franke DD, Yolcu ES, Alard P, Kosiewicz MM, Shirwan H.

Mol Immunol. 2007 Apr;44(11):2884-92. Epub 2007 Feb 26.

Supplemental Content

Loading ...
Support Center